Open access · CC-BY
via OpenAlex
Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection
Eugene Paul Duff, Henrik Zetterberg, Amanda Heslegrave, Abbas Dehghan, Paul Elliott, Naomi E. Allen, Heiko Runz, Rhiannon Laban, Elena Veleva, Christopher D. Whelan, Benjamin B. Sun, Paul McMahan Matthews
Nature Medicine · 2025 · ▲ 63 citations
Abstract
Previous studies have suggested that systemic viral infections may increase risks of dementia. Whether this holds true for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus infections is unknown. Determining this is important for anticipating the potential future incidence of dementia. To begin to do this, we measured plasma biomarkers linked to Alzheimer's disease pathology in the UK Biobank before and after serology-confirmed SARS-CoV-2 infections. SARS-CoV-2 infection was associated with biomarkers associated with β-amyloid pathology: reduced plasma Aβ42:Aβ40 ratio and, in more vulnerable participants, lower plasma Aβ42 and higher plasma pTau-181. The plasma biomarker changes were greater in participants who had been hospitalized with COVID-19 or had reported hypertension previously. We showed that the changes in biomarkers were linked to brain structural imaging patterns associated with Alzheimer's disease, lower cognitive test scores and poorer overall health evaluations. Our data from this post hoc case-control matched study thus provide observational biomarker evidence that SARS-CoV-2 infection can be associated with greater brain β-amyloid pathology in older adults. While these results do not establish causality, they suggest that SARS-CoV-2 (and possibly other systemic inflammatory diseases) may increase the risk of future Alzheimer's disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41591-024-03426-4
- Canonical
- link ↗
- Fetched
- 2026-11-16 MST
Cite this
APA
Duff, E.P., Zetterberg, H., Heslegrave, A., Dehghan, A., Elliott, P., Allen, N.E., Runz, H., Laban, R., Veleva, E., Whelan, C.D., Sun, B.B., & Matthews, P.M. (2025). Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. <em>Nature Medicine</em>. https://doi.org/10.1038/s41591-024-03426-4
Vancouver
Duff EP, Zetterberg H, Heslegrave A, Dehghan A, Elliott P, Allen NE, et al. Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. Nature Medicine. 2025. doi:10.1038/s41591-024-03426-4.
BibTeX
@article{eugene2025Plasma,
title = {Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection},
author = {Eugene Paul Duff and Henrik Zetterberg and Amanda Heslegrave and Abbas Dehghan and Paul Elliott and Naomi E. Allen and Heiko Runz and Rhiannon Laban and Elena Veleva and Christopher D. Whelan and Benjamin B. Sun and Paul McMahan Matthews},
journal = {Nature Medicine},
year = {2025},
doi = {10.1038/s41591-024-03426-4},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
medRxiv 2024
Preprint · OA
Plasma proteomic evidence for increased Alzheimer’s disease-related brain pathology after SARS-CoV-2 infection
JAMA Neurology 2019
Open access · OA
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
University of Cambridge 2025
Open access · US-GOV
Met-Pro Study: The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
Proteomes 2016
Open access · CC-BY
The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer’s Disease
Alzheimer s & Dementia 2018
Open access · CC-BY
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
ScholarsArchive (Brigham Young University) 2013
Preprint · OA